Technical Analysis for DCPH - Deciphera Pharmaceuticals, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | N/A | Down | Down |
| See historical DCPH trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Apr 25 | MACD Bearish Centerline Cross | Bearish | 0.00% |
| Apr 25 | Outside Day | Range Expansion | 0.00% |
| Apr 25 | Wide Bands | Range Expansion | 0.00% |
| Apr 25 | Down 3 Days in a Row | Weakness | 0.00% |
| Apr 25 | Oversold Stochastic | Weakness | 0.00% |
| Apr 24 | Wide Bands | Range Expansion | -1.40% |
| Apr 23 | 50 DMA Resistance | Bearish | -2.51% |
| Apr 23 | MACD Bearish Signal Line Cross | Bearish | -2.51% |
| Apr 23 | 180 Bearish Setup | Bearish Swing Setup | -2.51% |
| Apr 23 | Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -2.51% |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
Deciphera Pharmaceuticals, LLC is a United-States based clinical-stage biopharmaceutical company. The Company provides treatment for cancer patients. The Company focuses on developing tumor-targeted and immuno-targeted kinase inhibitors. Its switch control inhibitor platform is engaged in producing kinase inhibitors with distinct profiles and anti-cancer effects. Its tumor-targeting therapies include DCC-2618. DCC-2618 is a pan-KIT and PDGFR alpha kinase switch control inhibitor in clinical development for the treatment of KIT and/or Platelet-derived growth factor receptor alpha-driven cancers, including gastrointestinal stromal tumors, glioblastoma multiforme and systemic mastocytosis. Its Immuno-Targeted Therapies include DCC-3014 and Rebastinib. DCC-3014 is a potent and highly-selective immunokinase inhibitor targeting colony stimulating factor receptor 1 (CSF1R). Rebastinib is a TIE2 inhibitor targeting TIE2 expressing macrophages. Rebastinib is in the clinical development stage.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more DCPH news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 29.98 |
| 52 Week Low | 15.15 |
| Average Volume | 132,011 |
| 200-Day Moving Average | 0.0 |
| 50-Day Moving Average | 24.3912 |
| 20-Day Moving Average | 23.5845 |
| 10-Day Moving Average | 24.104 |
| Average True Range | 1.7585 |
| ADX | 20.54 |
| +DI | 13.28 |
| -DI | 20.55 |
| Chandelier Exit (Long, 3 ATRs ) | 22.5545 |
| Chandelier Exit (Short, 3 ATRs ) | 24.4655 |
| Upper Bollinger Band | 27.78 |
| Lower Bollinger Band | 19.389 |
| Percent B (%b) | 0.38 |
| BandWidth | 35.578452 |
| MACD Line | -0.0777 |
| MACD Signal Line | 0.0819 |
| MACD Histogram | -0.1596 |
| Fundamentals | Value |
|---|---|
| Market Cap | 720.23 Million |
| Num Shares | 31.9 Million |
| EPS | -16.03 |
| Price-to-Earnings (P/E) Ratio | -1.41 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 0.00 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 25.27 | ||||
| Resistance 3 (R3) | 25.45 | 24.73 | 24.82 | ||
| Resistance 2 (R2) | 24.73 | 24.04 | 24.64 | 24.67 | |
| Resistance 1 (R1) | 23.65 | 23.62 | 23.29 | 23.46 | 24.52 |
| Pivot Point | 22.93 | 22.93 | 22.75 | 22.84 | 22.93 |
| Support 1 (S1) | 21.84 | 22.24 | 21.48 | 21.66 | 20.60 |
| Support 2 (S2) | 21.12 | 21.81 | 21.03 | 20.45 | |
| Support 3 (S3) | 20.04 | 21.12 | 20.30 | ||
| Support 4 (S4) | 19.85 |
